The human JC polyomavirus (JCPyV): virological background and clinical implications

Authors

  • Hans H. Hirsch,

    Corresponding author
    1. Division of Infection Diagnostics (‘Institute for Medical Microbiology’), Department Biomedicine (Haus Petersplatz), University of Basel, Basel
    2. Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    • Transplantation & Clinical Virology, Department Biomedicine (Haus Petersplatz), University of Basel, Basel
    Search for more papers by this author
  • Piotr Kardas,

    1. Transplantation & Clinical Virology, Department Biomedicine (Haus Petersplatz), University of Basel, Basel
    Search for more papers by this author
  • Denise Kranz,

    1. Transplantation & Clinical Virology, Department Biomedicine (Haus Petersplatz), University of Basel, Basel
    Search for more papers by this author
  • Celine Leboeuf

    1. Transplantation & Clinical Virology, Department Biomedicine (Haus Petersplatz), University of Basel, Basel
    Search for more papers by this author

Hans H. Hirsch, Department Biomedicine - Haus Petersplatz, University of Basel, Petersplatz 10, CH-4003 Basel, Switzerland. e-mail: hans.hirsch@unibas.ch

Abstract

JC polyomavirus (JCPyV) was the first of now 12 PyVs detected in humans, when in 1964, PyV particles were revealed by electron microscopy in progressive multifocal leukoencephalopathy (PML) tissues. JCPyV infection is common in 35–70% of the general population, and the virus thereafter persists in the renourinary tract. One third of healthy adults asymptomatically shed JCPyV at approximately 50 000 copies/mL urine. PML is rare having an incidence of <0.3 per 100 000 person years in the general population. This increased to 2.4 per 1000 person years in HIV-AIDS patients without combination antiretroviral therapy (cART). Recently, PML emerged in multiple sclerosis patients treated with natalizumab to 2.13 cases per 1000 patients. Natalizumab blocks α4-integrin-dependent lymphocyte homing to the brain suggesting that not the overall cellular immunodeficiency but local failure of brain immune surveillance is a pivotal factor for PML. Recovering JCPyV-specific immune control, e.g., by starting cART or discontinuing natalizumab, significantly improves PML survival, but is challenged by the immune reconstitution inflammatory syndrome. Important steps of PML pathogenesis are undefined, and antiviral therapies are lacking. New clues might come from molecular and functional profiling of JCPyV and PML pathology and comparison with other replicative pathologies such as granule cell neuronopathy and (meningo-)encephalitis, and non-replicative JCPyV pathology possibly contributing to some malignancies. Given the increasing number of immunologically vulnerable patients, a critical reappraisal of JCPyV infection, replication and disease seems warranted.

Ancillary